Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2023-03-09
- Target Recruit Count
- 38
- Registration Number
- NCT05536102
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05507112
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eye & ENT Hospital of Fudan University
- Target Recruit Count
- 111
- Registration Number
- NCT05494190
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Shandong Provincial ENT Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
🇨🇳Eye & ENT Hospital, Fudan University, Shanghai, Shanghai, China
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 582
- Registration Number
- NCT05489211
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Phanes Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT05482893
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
🇺🇸Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT05479240
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 36
- Registration Number
- NCT05472948
- Locations
- 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 200
- Registration Number
- NCT05464030
- Locations
- 🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸California Cancer Associates for Research & Excellence, Inc., Fresno, California, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 116
- Registration Number
- NCT05451719
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 70
- Registration Number
- NCT05438706
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.